

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4038


TITLE: Molecular Determinants of Antiestrogen and Drug Sensitivity in Breast Carcinoma Cells

PRINCIPAL INVESTIGATOR(S): Dr. Igor B. Roninson

CONTRACTING ORGANIZATION: University of Illinois at Chicago  
Chicago, Illinois 60612-7205

REPORT DATE: August 14, 1995

TYPE OF REPORT: Annual



PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19951018 034

DTIC QUALITY INSPECTED 8

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>	<b>2. REPORT DATE</b> August 14, 1995	<b>3. REPORT TYPE AND DATES COVERED</b> Annual July 15, 1994 - July 14, 1995	
<b>4. TITLE AND SUBTITLE</b> Molecular Determinants of Antiestrogen and Drug Sensitivity in Breast Carcinoma Cells		<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4038	
<b>6. AUTHOR(S)</b> Dr. Igor B. Roninson			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Illinois 809 S. Marshfield, Room 502MB Chicago, Illinois 60612-7205		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>			
<b>12a. DISTRIBUTION/AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited		<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b>  MCF7 breast carcinoma cells were rendered susceptible to infection with recombinant ecotropic retroviruses, through transfection with the gene for murine ecotropic receptor and by testing individual transfectants for infectability. A genetic suppressor element (GSE), derived from the BCL2 gene which inhibits active cell death (apoptosis), was introduced into MCF7 cells. The BCL2-derived GSE sensitized MCF7 cells to different chemotherapeutic drugs, indicating that BCL2 is an important determinant of chemoresistance of these cells. A retroviral library of normalized cDNA fragments, derived from HeLa cell line, was introduced into MCF7 cells, and selection of GSEs that render MCF7 cells resistant to doxorubicin was initiated. A normalized cDNA library is also being prepared from MCF7 cells, for use as a source of GSEs conferring resistance to tamoxifen.			
<b>14. SUBJECT TERMS</b> Chemotherapy/tamoxifen/drug resistance/genetic suppressor elements		<b>15. NUMBER OF PAGES</b> 19	
		<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited

*enclosure*

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

**Block 1.** Agency Use Only (Leave blank).

**Block 2.** Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3.** Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4.** Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5.** Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6.** Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7.** Performing Organization Name(s) and Address(es). Self-explanatory.

**Block 8.** Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9.** Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

**Block 10.** Sponsoring/Monitoring Agency Report Number. (If known)

**Block 11.** Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a.** Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b.** Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13.** Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14.** Subject Terms. Keywords or phrases identifying major subjects in the report.

**Block 15.** Number of Pages. Enter the total number of pages.

**Block 16.** Price Code. Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19.** Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20.** Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

IR ✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

IR ✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

IR ✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Elton Bonner 8/11/95  
PI - Signature Date




TABLE OF CONTENTS

Front Cover	1
SF 298 Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Conclusions	8
References	9
Appendix	11
Figure Legends	11
Figures (1-8)	12

<b>Accession For</b>	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/ _____	
<b>Availability Codes</b>	
Dist	Avail and/or Special
A-1	

## Introduction

Chemotherapy, based on cytotoxic drugs or hormone antagonists, is widely used as either adjuvant or primary treatment at all stages of breast cancer (1). The drug regimens that are most commonly used for breast cancer include a combination of cyclophosphamide, methotrexate and 5-fluorouracyl (CMF), or doxorubicin (presently the most powerful drug in this group) which is most often used as a single agent in the second line of treatment. In addition, taxol was shown by recent studies to produce significant objective responses in breast cancer. Aside from these chemotherapeutic compounds that are used in different types of cancer, another, breast cancer-specific class of drugs is used in the treatment of estrogen receptor-positive tumors. These agents are antiestrogens, the most widely used of which is tamoxifen (1). The objective of the present grant is to identify genes that determine the sensitivity of human breast carcinoma cells to agents used in breast cancer treatment, including antiestrogens (tamoxifen) and cytotoxic drugs (doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracyl, taxol).

Our approach to the identification of chemotherapeutic sensitivity genes is based on the isolation of genetic suppressor elements (GSEs), derived from such genes and inducing cellular resistance or sensitivity to the corresponding agents. GSEs are short cDNA fragments that counteract the genes from which they are derived by encoding inhibitory peptides or antisense RNAs (2). We have previously developed the methodology for GSE selection from retroviral libraries carrying short random fragments of normalized (uniform-abundance) cDNA from mammalian cells (3,4). Using this approach, we identified several GSEs conferring resistance to anticancer drugs or inducing neoplastic transformation (4-6). The same strategy is being used in the present project to identify GSEs that render breast carcinoma cells resistant or sensitive to chemotherapeutic agents. In one arm of the project, GSEs inducing resistance to a metabolite of tamoxifen will be cloned by expression selection in MCF7 cells. The cloned GSEs will be used to isolate full-length cDNA sequences of the corresponding genes, and the effects of individual GSEs on hormone responsiveness and drug resistance will be investigated. In another arm of the project, different GSEs inducing resistance or sensitivity to chemotherapeutic drugs in various cell types, will be tested for their ability to make MCF7 cells resistant to cytotoxic drugs and antiestrogens. The genes giving rise to such GSEs would constitute likely determinants of chemotherapeutic sensitivity in breast carcinoma.

## Body

### 1. Development of a recipient MCF7/ETR cell line

The most efficient of the protocols used in our laboratory for gene transfer into mammalian cells is retroviral transduction, using 293-derived BOSC 23 packaging cells (7). These cells, however, produce ecotropic virus, which would normally infect only mouse or rat cells that express the

ecotropic receptor (ETR) on their surface. To render MCF7 human breast carcinoma cells susceptible to infection with ecotropic retroviruses, we co-transfected these cells (obtained from ATCC) with pJET2 plasmid carrying the murine ETR gene (8), and D3PVBleo plasmid, carrying a phleomycin resistance gene, using a standard transfection protocol based on calcium phosphate coprecipitation. After three weeks of selection with 20-70  $\mu\text{g/ml}$  phleomycin, about 80 transfectant clones were obtained. 43 of these clones were individually tested for susceptibility to infection with retroviral vector LNCX (9), carrying the neo (G418) resistance gene, and generated by transient transfection into BOSC 23 ecotropic packaging cells. The infectability of individual clones was evaluated by G418 selection. 3 clones survived G418 to a significant degree, and the best of these clones, designated MCF7/ETR, showed G418 resistance in nearly 100% of cells after ecotropic virus infection. This clone was selected for further studies.

## 2. Characterization of tamoxifen and drug sensitivity in MCF7 cells

An unexpected logistic problem arose with obtaining an antiestrogen for this study. We have originally proposed to use 4-hydroxytamoxifen (4-OHTAM), a metabolite of tamoxifen which has been predominantly utilized in the literature for *in vitro* cytotoxicity studies (10). 4-OHTAM is not commercially available, and we have therefore requested a sample from a company (ICI), which in the past provided this reagent to researchers. We were eventually informed that this company no longer holds a license for 4-OHTAM, and we were directed to a French company as the new license holder. The latter company, however, did not reply to our request for this reagent. We have therefore decided to use tamoxifen itself, rather than 4-OHTAM, for our tissue culture work. The only disadvantage of tamoxifen relative to 4-OHTAM is that it requires approximately two orders of magnitude higher concentration for *in vitro* cytotoxicity (personal communication from Dr. Craig Jordan). Since tamoxifen is readily available from commercial sources, we have substituted 4-OHTAM with tamoxifen for all the relevant studies in this project.

We have analyzed the sensitivity of MCF7/ETR cells to tamoxifen, as well as doxorubicin (adriamycin), vincristine, cytarabine, and cisplatin, using a standard plating efficiency colony assay. Representative assays are shown in Figs. 1-5, where MCF7/ETR cells, transduced with an insert-free LNCX retroviral vector and selected with G418, were used as a control to study the effects of a BCL2-derived GSE (see below) on drug sensitivity. In these assays, cells were exposed to drugs for a short period of time (1.5-4 hrs, except for tamoxifen which required 24 hr treatment) and then allowed to form colonies for 5-8 days. These conditions mimic bolus administration, the most common form of therapy administration in the clinics, and reveal primarily the cytotoxic rather than the cytostatic effects of the drugs.

## 3. Chemosensitization of MCF7 cells by a GSE from the BCL2 gene

Active cell death (apoptosis) is a physiological process

which is primarily responsible for the cytotoxicity of many anticancer drugs (11). Apoptosis induced by many different stimuli is inhibited by the product of the BCL2 oncogene (12). Gene transfer and expression of BCL2 in BCL2-negative cells has been shown to confer resistance to different classes of anticancer drugs, indicating that BCL2 is a multidrug resistance gene (13,14).

Using the single-gene GSE selection strategy (3), we have previously isolated a single sense-oriented peptide-encoding fragment of BCL2 cDNA which acted as a GSE, sensitizing BCL2-expressing cells to drug induced apoptosis. The original selection had been carried out in a B-cell leukemia cell line. The isolated GSE, termed 2-7, and its variant, differing by a single amino acid and designated 2-25, were found to increase drug sensitivity in AA2 and HL60 leukemia and SW480 carcinoma cell line (15). We have now tested this GSE in MCF7 breast carcinoma cells, and found that the efficacy of the BCL2-derived GSE was the highest in this cell line. Fig. 1 shows that 2-7 sensitizes MCF7 cells to vincristine by approximately one order of magnitude. Significant sensitization of MCF7 cells by the BCL2-derived GSE was also observed with tamoxifen, doxorubicin, cytarabine and cisplatin (Figs. 2-5). The GSE, which encodes a short (28 amino acids) peptide from the middle of the BCL2 protein, was at least as efficient in MCF7 cells as a construct expressing full-length antisense RNA of BCL2, expressed from the same LNCX retroviral vector.

When investigating the effect of the 2-7 element on BCL2 gene expression, we have found to our surprise that this peptide-encoding GSE drastically reduces the steady-state level of BCL2 mRNA in MCF7 cells. This is illustrated by an experiment in Fig. 6, where BCL2 mRNA expression was analyzed by a RT-PCR assay (16), using the following BCL2-specific primers: GTGGCCTTCTTTGAGTTCGG (sense) and GGCTCAGATAGGCACCCAGG (antisense). Primers amplifying  $\beta_2$ -microglobulin cDNA (16) were used as an internal control. The mechanism of this striking effect is as yet unknown.

#### 4. Isolation of GSEs inducing doxorubicin resistance in MCF7 cells

Doxorubicin (Adriamycin) is the most clinically efficient chemotherapeutic agent currently in use for breast cancer (1). To identify the genes responsible for doxorubicin sensitivity in breast carcinoma, we have used MCF7/ETR cells to carry out the selection of GSEs conferring resistance to doxorubicin, starting from a normalized random fragment cDNA library that we had constructed from human HeLa cells (5). The library, which contains about  $2 \times 10^7$  recombinant clones, was introduced by retroviral transduction into  $4 \times 10^7$  MCF7/ETR cells, on four P150 plates, which were then subjected to doxorubicin selection under the following protocol: 2.5 hrs exposure to 150 nM doxorubicin, followed by 2 days without drug, then another drug treatment under the same conditions, and the final round of treatment, this time increasing the drug dose to 500 nM. After this selection, only 6 surviving colonies in a with the control population, infected with the LNCX insert-free vector virus, but library-

containing cells survived at an average rate of 27 colonies per plate. Over 60 individual colonies were picked, expanded and frozen. Analysis of proviral inserts integrated in representative clones from this set by PCR (4) showed that most of the tested clones contained only single or a few inserts (Fig. 7). These results indicate that GSE selection is successfully proceeding in this system.

#### 5. Preparation of a population of normalized cDNA fragments from MCF-7 cells

The normalized cDNA library from HeLa cells, used for doxorubicin selection, is unlikely to be useful for tamoxifen selection, since genes responsible for antiestrogen sensitivity most probably are not expressed in HeLa cells. We are therefore constructing a normalized random fragment cDNA library from MCF7 breast carcinoma cells. Poly(A)<sup>+</sup> RNA was isolated from MCF7 cells and used to synthesize cDNA by reverse transcription using a random primer, conjugated at its 5' end with an adaptor that carries translation termination codons in all three open reading frames and the Sall site. Another adaptor, carrying three translation initiation codons and the Sall site, was ligated to both ends of the cDNA fragments; this adaptor will be subsequently removed from the 3' ends after ClaI digestion. The cDNA population prepared by this procedure would have different adaptors at the 5' and 3' ends, which will simplify subsequent orientation of the selected GSEs. The double-stranded cDNA fragments, ranging from 150 to 1000 bp in size, were successfully amplified by PCR using adaptor-specific primers (Fig. 8). We are currently optimizing the conditions for hydroxyapatite separation of single-stranded and double-stranded DNA, as a preliminary step to the normalization of our MCF7 cDNA preparation.

#### **Conclusions**

In the course of the above described studies, we have established that (i) the apoptosis suppressor, BCL2, plays a critical role in chemosensitivity of MCF7 breast carcinoma cells and thus presents a promising target for chemosensitization of breast cancer; (ii) a sense-oriented GSE from BCL2 decreases BCL2 mRNA levels in MCF7, indicating the existence of a previously unknown and potentially exploitable mechanism of BCL2 regulation; (iii) a normalized cDNA library from human HeLa cells is a suitable source for the isolation of GSEs that confer doxorubicin resistance in breast carcinoma cells. Other studies in this project are still at a stage which is too early to draw specific conclusions.

The originally proposed studies will be continued with the following changes:

(1) Tamoxifen instead of 4-OHTAM will be used to select for GSEs conferring antiestrogen resistance.

(2) We have originally planned to clone GSEs conferring chemotherapeutic drug resistance in other cell types and then test them on MCF7 cells. However, MCF7/ETR cells proved to be an appropriate recipient cell line to isolate GSEs conferring doxorubicin resistance from a HeLa-derived normalized cDNA

library, and therefore doxorubicin-resistance GSEs will be selected directly in MCF7/ETR cells.

(3) The striking chemosensitizing effect of the BCL2-derived GSE in MCF7 cells warrants further analysis. We will therefore determine if the GSE indeed functions through peptide production and whether it affects the regulation of BCL2 mRNA stability, translation or protein modification. We will also seek additional funding to fully explore this exciting observation.

## References

1. Harris, J.R., Morrow, M., and Bonadonna, G. (1993). Cancer of the breast. In: *Cancer: Principles and Practice of Oncology*, 4th Edition (DeVita, V.T., Hellman, S. and Rosenberg, S.A., eds.), Philadelphia: Lippincott, pp. 1264-1332.
2. Holzmayer, T.A., Pestov, D.G., and Roninson, I.B. (1992). Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments. *Nucleic Acids Res.* 20, 711-717.
3. Gudkov, A.V., Zelnick, C., Kazarov, A.R., Thimmapaya, R., Suttle, D.P., Beck, W.T., and Roninson, I.B. (1993). Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. *Proc. Natl. Acad. Sci. USA* 90, 3231-3235.
4. Gudkov, A.V., Kazarov, A.R., Thimmapaya, R., Axenovich, S., Mazo, I., and Roninson, I.B. (1993). Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. *Proc. Natl. Acad. Sci. USA*, in press.
5. D.J. Kirschling, V. Levenson, E. Kandel, Y. Xuan, S. Salov, V. Fedosova, and I.B. Roninson, unpublished data.
6. A.V. Gudkov, I.A. Mazo, A.R. Kazarov, and I.B. Roninson, unpublished data.
7. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. *Proc. Natl. Acad. Sci. USA* 90, 8392-8396.
8. Albritton, L.M., Tseng, L., Scadden, D., and Cunningham, J.M. (1989). A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. *Cell* 57, 659-666.
9. Miller, A.D. and Rosman, G.J. (1989). Improved retroviral vectors for gene transfer and expression. *Biotechniques* 7, 980-986.
10. Clarke, R. and Lippman, M.E. (1993). Acquisition of antiestrogen resistance in breast cancer. In: *Drug Resistance in Oncology*, B.A. Teicher, Ed., Marcel Dekker, p.p. 501-536.
11. Fisher, D.E. Apoptosis in cancer therapy: crossing the threshold. *Cell* 78:539-542, 1994.
12. Reed, J.C. Bcl-2 and the regulation of programmed cell death. *J. Cell Biol.* 124:1-6, 1994.
13. Walton, M.I., Whysong, D., O'Connor, P.M., Hockenbery, D., Korsmeyer, S.J., Kohn, K.W. (1993). Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin

- induced apoptosis. *Cancer Res.* 53, 1853-1861.
14. Miyashita, T., Reed, J.C. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. *Blood* 81, 151-157.
  15. Tarasewicz, D.G., Schott, B., Xuan, Y., Salov, S., Holzmayer, T.A. and Roninson, I.B. (1995). A genetic suppressor element inhibits BCL2 gene expression and sensitizes tumor cells to anticancer drugs. Manuscript in preparation.
  16. Noonan, K.E., Beck, C., Holzmayer, T. A., Chin, J.E., Wunder, J.S., Andrulis, I.L., Gazdar, A.F., Willman, C.L., Griffith, B., Von Hoff, D.D., and Roninson, I.B. (1990). Quantitative analysis of *MDR1* (multidrug resistance) gene expression in human tumors by polymerase chain reaction. *Proc. Natl. Acad. Sci. USA* 87, 7160-7164.

## Appendix

### Figure Legends

Fig. 1. Effects of clone 2-7 (BCL2-derived GSE) and of a clone expressing antisense RNA of *BCL2* in the same LNCX vector on vincristine resistance of MCF7/ETR cells. Cells were treated with vincristine for 1.5 hrs and then cultured for 8 days. Cell survival (relative to untreated cells) was determined by a plating efficiency colony assay.

Fig. 2. Effects of clone 2-25 (a variant of 2-7 with a single amino acid change) and of a clone expressing antisense RNA of *BCL2* on tamoxifen resistance of MCF7/ETR cells. Cells were treated with tamoxifen for 24 hrs and then cultured for 8 days. Cell survival (relative to untreated cells) was determined by a plating efficiency colony assay.

Fig. 3. Effects of clone 2-7 and of a clone expressing antisense RNA of *BCL2* on doxorubicin resistance of MCF7/ETR cells. Cells were treated with doxorubicin for 2.5 hrs and then cultured for 5 days. Cell survival (relative to untreated cells) was determined by a plating efficiency colony assay.

Fig. 4. Effects of clone 2-7 and of a clone expressing antisense RNA of *BCL2* on cytarabine resistance of MCF7/ETR cells. Cells were treated with cytarabine for 1.5 hrs and then cultured for 8 days. Cell survival (relative to untreated cells) was determined by a plating efficiency colony assay.

Fig. 5. Effects of clone 2-7 and of a clone expressing antisense RNA of *BCL2* on cisplatin resistance of MCF7/ETR cells. Cells were treated with cisplatin for 4 hrs and then cultured for 8 days. Cell survival (relative to untreated cells) was determined by a plating efficiency colony assay.

Fig. 6. Effects of clones 2-7, 2-25 and antisense *BCL2* RNA on *BCL2* mRNA expression in MCF7/ETR cells. Analysis was carried out by RT-PCR, using  $\beta_2$ -microglobulin (B2M) as an internal control.

Fig. 7. Recovery of cDNA inserts from retroviral vectors integrated in the genomic DNA of doxorubicin-selected clones of MCF7/ETR cells. The inserts were amplified by PCR using primers derived from vector and adaptor sequence. M: 123 bp ladder. 1-16: individual cell clones.

Fig. 8. Electrophoretic analysis of the population of cDNA fragments from MCF7 cells, amplified by PCR using adaptor-derived primers. M1: "1 kb ladder" size standards (BRL). M2: 123 bp ladder. 1-3: cDNA fragments, amplified by PCR from 1:10, 1:100 and 1:1000 dilutions of the ligation mixture.

# Sensitization of MCF-7 to vincristine by BCL2 GSE or full-length antisense RNA




FIGURE 1

# Sensitization of MCF-7 to tamoxifen by BCL2 GSE or full-length antisense RNA




FIGURE 2

# Sensitization of MCF-7 to doxorubicin by BCL2 GSE or full-length antisense RNA




FIGURE 3

# Sensitization of MCF-7 to cytarabine by BCL2 GSE or full-length antisense RNA




FIGURE 4

# Sensitization of MCF-7 to cisplatin by BCL2 GSE or full-length antisense RNA




FIGURE 5



FIGURE 6

M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M




FIGURE 7

M1 1 2 3 M2




FIGURE 8